|
La Jolla Pharmaceutical Company |
|
|
6455 Nancy Ridge Drive
San Diego, CA 92121-2249 USA
phone:(858) 452-6600
fax:(858) 626-2851
|
|
| Symbol |
LJPC |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.ljpc.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Therapeutics for antibody-mediated diseases. |
|
| Management |
| Deirdre Y. Gillespie, M.D., President and Chief Executive Officer; Matthew D. Linnik, Ph.D., Chief Scientific Officer and Executive Vice President; Michael Tansey, M.D., Ph.D., Executive Vice President and Chief Medical Officer; Josefina Elchico, Vice President of Quality Operations; Paul C. Jenn, Ph.D., Vice President of Product Development; Gail A. Sloan, CPA, Vice President of Finance and Secretary; Lisa Koch Hulle, RAC, MTOPRA, Vice President of Regulatory Affairs; Luke Seikkula, Vice President of Manufacturing; Andrew Wiseman, Ph.D., Senior Director of Investor Relations |
| |
|
|
|
|
|
|
|
| Keywords |
| lupus, stroke, immune system, autoimmune, antibody |
|
|
|
| Description |
|
La Jolla Pharmaceutical Company is focused on the research and development of highly specific therapeutic products for the treatment of certain life-threatening antibody-mediated diseases. |
|
| Products / Services |
The Company's drug candidates, called Toleragens, are formulated to treat the underlying cause of many antibody-mediated diseases without these severe, negative side effects.
|
|
| Technology / Differentiation |
| These diseases, including autoimmune conditions such as lupus and antibody-mediated stroke, are caused by abnormal B cell production of antibodies that attack healthy tissues. Known treatments for these autoimmune disorders address only symptoms of the disease, or non-specifically suppress the normal operation of the immune system, which often results in severe, negative side effects and hospitalization. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
